OcuMension

formerly OcuMension TherapeuticsIPO

Public · Shanghai, China · Founded 2018

Headquarters
Shanghai
Employees
201–500
Founded
2018
Business Model
B2B
Last Round
Series CJan 2019
Rounds
2
Type
Public

About

Ocumension Therapeutics is a China-based ophthalmic pharmaceutical platform company dedicated to identifying, developing, and commercializing first- or best-in-class treatments for patients suffering from ocular diseases. The company licenses and commercializes eye therapies from global partners, including EyePoint Pharmaceuticals' Durasert products, for the Chinese market, and has entered collaborations such as with Shandong Boan for posterior segment disease treatments. Founded in May 2018 and headquartered in Shanghai, Ocumension is listed on the Hong Kong Stock Exchange (1477.HK).

Summary

OcuMension is a Life Sciences company based in Shanghai, China, founded in 2018. Its most recent funding was a Series C round in Jan 2019. Investors include Hong Kong Stock Exchange, Temasek and General Atlantic.

Tech & App Stack

1 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

IPOJul 2020
$184.0M

Sign up to see all 3 rounds

Series B through IPO — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

OcuMension on Indexed.vc
<a href="https://indexed.vc/companies/ocumension"><img src="https://indexed.vc/api/badge/company/ocumension" alt="OcuMension on Indexed.vc" width="260" height="76" /></a>